BNP Paribas Arbitrage SA Has $28,000 Holdings in Kala Pharmaceuticals Inc (NASDAQ:KALA)

BNP Paribas Arbitrage SA raised its stake in shares of Kala Pharmaceuticals Inc (NASDAQ:KALA) by 877.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,410 shares of the company’s stock after purchasing an additional 3,061 shares during the period. BNP Paribas Arbitrage SA’s holdings in Kala Pharmaceuticals were worth $28,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Matisse Capital acquired a new stake in shares of Kala Pharmaceuticals in the first quarter valued at $361,000. Deutsche Bank AG increased its stake in shares of Kala Pharmaceuticals by 349.6% in the fourth quarter. Deutsche Bank AG now owns 268,054 shares of the company’s stock valued at $1,310,000 after buying an additional 208,436 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Kala Pharmaceuticals by 79.4% in the fourth quarter. Geode Capital Management LLC now owns 199,935 shares of the company’s stock valued at $977,000 after buying an additional 88,484 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Kala Pharmaceuticals by 62.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 255,760 shares of the company’s stock valued at $1,251,000 after buying an additional 98,591 shares in the last quarter. Finally, Sofinnova Investments Inc. increased its stake in shares of Kala Pharmaceuticals by 365.8% in the fourth quarter. Sofinnova Investments Inc. now owns 445,516 shares of the company’s stock valued at $2,178,000 after buying an additional 349,861 shares in the last quarter. Institutional investors own 69.92% of the company’s stock.

Shares of KALA stock opened at $5.11 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 10.30 and a quick ratio of 9.93. The stock has a market capitalization of $173.14 million, a P/E ratio of -2.06 and a beta of 1.91. Kala Pharmaceuticals Inc has a 12 month low of $4.03 and a 12 month high of $14.95.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.75) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.75). The firm had revenue of $1.39 million during the quarter, compared to analyst estimates of $0.96 million. Equities analysts anticipate that Kala Pharmaceuticals Inc will post -2.86 earnings per share for the current fiscal year.

A number of brokerages recently commented on KALA. Zacks Investment Research lowered Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 26th. Wedbush set a $51.00 price objective on Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, May 14th. BidaskClub upgraded Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Finally, Oppenheimer began coverage on Kala Pharmaceuticals in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.21.

In other news, Director Howard B. Rosen acquired 5,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average cost of $5.42 per share, for a total transaction of $27,100.00. Following the completion of the transaction, the director now directly owns 8,240 shares in the company, valued at $44,660.80. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 30.77% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “BNP Paribas Arbitrage SA Has $28,000 Holdings in Kala Pharmaceuticals Inc (NASDAQ:KALA)” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/06/15/bnp-paribas-arbitrage-sa-has-28000-holdings-in-kala-pharmaceuticals-inc-nasdaqkala.html.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Further Reading: Beta

Want to see what other hedge funds are holding KALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kala Pharmaceuticals Inc (NASDAQ:KALA).

Institutional Ownership by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.